Our understanding of the genetic causes of disease has reached a critical stage, putting us on the cusp of being able to develop functional cures for a large number of rare genetic disorders, says Global Life Sciences Co-Portfolio Manager, Andy Acker.
Gene therapy has the potential to provide “one and done” treatments that can correct genetic defects that cause life-threatening diseases.
Biopharmaceutical companies are working on treatments for the more than 7000 known genetic disorders, including haemophilia, muscular dystrophy and spinal muscular atrophy – the biggest genetic cause of infant death.
As investors, we recognise the importance of looking not only at large, public companies working on gene therapies, but also at the smaller innovators that have the potential to be disruptive.
Video recorded on 1 September 2018.
Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.
The information in this article does not qualify as an investment recommendation.
For promotional purposes.
Anything non-factual in nature is an opinion of the author(s), and opinions are meant as an illustration of broader themes, are not an indication of trading intent, and are subject to change at any time due to changes in market or economic conditions. It is not intended to indicate or imply that any illustration/example mentioned is now or was ever held in any portfolio. No forecasts can be guaranteed and there is no guarantee that the information supplied is complete or timely, nor are there any warranties with regard to the results obtained from its us.
Please read the following important information regarding funds related to this article.